149 related articles for article (PubMed ID: 29255149)
1. BCAT1 is a New MR Imaging-related Biomarker for Prognosis Prediction in IDH1-wildtype Glioblastoma Patients.
Cho HR; Jeon H; Park CK; Park SH; Kang KM; Choi SH
Sci Rep; 2017 Dec; 7(1):17740. PubMed ID: 29255149
[TBL] [Abstract][Full Text] [Related]
2. Assessment of bevacizumab resistance increased by expression of BCAT1 in IDH1 wild-type glioblastoma: application of DSC perfusion MR imaging.
Cho HR; Hong B; Kim H; Park CK; Park SH; Park S; Choi SH
Oncotarget; 2016 Oct; 7(43):69606-69615. PubMed ID: 27626306
[TBL] [Abstract][Full Text] [Related]
3. Enrichment of branched chain amino acid transaminase 1 correlates with multiple biological processes and contributes to poor survival of IDH1 wild-type gliomas.
Yi L; Fan X; Li J; Yuan F; Zhao J; Nistér M; Yang X
Aging (Albany NY); 2021 Jan; 13(3):3645-3660. PubMed ID: 33493139
[TBL] [Abstract][Full Text] [Related]
4. BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1.
Tönjes M; Barbus S; Park YJ; Wang W; Schlotter M; Lindroth AM; Pleier SV; Bai AHC; Karra D; Piro RM; Felsberg J; Addington A; Lemke D; Weibrecht I; Hovestadt V; Rolli CG; Campos B; Turcan S; Sturm D; Witt H; Chan TA; Herold-Mende C; Kemkemer R; König R; Schmidt K; Hull WE; Pfister SM; Jugold M; Hutson SM; Plass C; Okun JG; Reifenberger G; Lichter P; Radlwimmer B
Nat Med; 2013 Jul; 19(7):901-908. PubMed ID: 23793099
[TBL] [Abstract][Full Text] [Related]
5. Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma.
Chaumeil MM; Larson PE; Woods SM; Cai L; Eriksson P; Robinson AE; Lupo JM; Vigneron DB; Nelson SJ; Pieper RO; Phillips JJ; Ronen SM
Cancer Res; 2014 Aug; 74(16):4247-57. PubMed ID: 24876103
[TBL] [Abstract][Full Text] [Related]
6. Increased RLIP76 expression in IDH1 wild‑type glioblastoma multiforme is associated with worse prognosis.
Wang Q; Zhang L; Cui Y; Zhang C; Chen H; Gu J; Qian J; Luo C
Oncol Rep; 2020 Jan; 43(1):188-200. PubMed ID: 31746408
[TBL] [Abstract][Full Text] [Related]
7. MR Imaging-Based Analysis of Glioblastoma Multiforme: Estimation of IDH1 Mutation Status.
Yamashita K; Hiwatashi A; Togao O; Kikuchi K; Hatae R; Yoshimoto K; Mizoguchi M; Suzuki SO; Yoshiura T; Honda H
AJNR Am J Neuroradiol; 2016 Jan; 37(1):58-65. PubMed ID: 26405082
[TBL] [Abstract][Full Text] [Related]
8. Prediction of IDH1 Mutation Status in Glioblastoma Using Machine Learning Technique Based on Quantitative Radiomic Data.
Lee MH; Kim J; Kim ST; Shin HM; You HJ; Choi JW; Seol HJ; Nam DH; Lee JI; Kong DS
World Neurosurg; 2019 May; 125():e688-e696. PubMed ID: 30735871
[TBL] [Abstract][Full Text] [Related]
9. Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults.
Olar A; Raghunathan A; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Goodman JC; Fuller GN
Ann Diagn Pathol; 2012 Jun; 16(3):161-70. PubMed ID: 22197544
[TBL] [Abstract][Full Text] [Related]
10. Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma.
Lasocki A; Tsui A; Gaillard F; Tacey M; Drummond K; Stuckey S
J Clin Neurosci; 2017 May; 39():170-175. PubMed ID: 28214089
[TBL] [Abstract][Full Text] [Related]
11. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
[TBL] [Abstract][Full Text] [Related]
12. Qualitative and Quantitative Analysis of IDH1 Mutation in Progressive Gliomas by Allele-Specific qPCR and Western Blot Analysis.
Perrech M; Dreher L; Röhn G; Stavrinou P; Krischek B; Toliat M; Goldbrunner R; Timmer M
Technol Cancer Res Treat; 2019 Jan; 18():1533033819828396. PubMed ID: 30943868
[TBL] [Abstract][Full Text] [Related]
13. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
[TBL] [Abstract][Full Text] [Related]
14. Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients.
Wang K; Wang Y; Fan X; Wang J; Li G; Ma J; Ma J; Jiang T; Dai J
Neuro Oncol; 2016 Apr; 18(4):589-97. PubMed ID: 26409566
[TBL] [Abstract][Full Text] [Related]
15. Targeting BCAT1 Combined with α-Ketoglutarate Triggers Metabolic Synthetic Lethality in Glioblastoma.
Zhang B; Peng H; Zhou M; Bao L; Wang C; Cai F; Zhang H; Wang JE; Niu Y; Chen Y; Wang Y; Hatanpaa KJ; Copland JA; DeBerardinis RJ; Wang Y; Luo W
Cancer Res; 2022 Jul; 82(13):2388-2402. PubMed ID: 35499760
[TBL] [Abstract][Full Text] [Related]
16. Dynamic Contrast-Enhanced T1-Weighted Perfusion Magnetic Resonance Imaging Identifies Glioblastoma Immunohistochemical Biomarkers via Tumoral and Peritumoral Approach: A Pilot Study.
Ozturk K; Soylu E; Tolunay S; Narter S; Hakyemez B
World Neurosurg; 2019 Aug; 128():e195-e208. PubMed ID: 31003026
[TBL] [Abstract][Full Text] [Related]
17. Morphologic patterns of noncontrast-enhancing tumor in glioblastoma correlate with IDH1 mutation status and patient survival.
Lasocki A; Gaillard F; Tacey M; Drummond K; Stuckey S
J Clin Neurosci; 2018 Jan; 47():168-173. PubMed ID: 28988652
[TBL] [Abstract][Full Text] [Related]
18. [Isocitrate dehydrogenase type I mutation as a prognostic factor in glioblastoma and a literature review].
de Quintana-Schmidt C; Alvarez-Holzapfel MJ; Nomdedeu-Guinot J; Bague-Rosell S; Gallego-Rubio O; Leidinger A; Salgado-Lopez L; Molet-Teixidó J
Neurocirugia (Astur); 2015; 26(6):276-83. PubMed ID: 26194445
[TBL] [Abstract][Full Text] [Related]
19. Driving with Both Feet: Supplementing AKG While Inhibiting BCAT1 Leads to Synthetic Lethality in GBM.
Meurs N; Nagrath D
Cancer Res; 2022 Jul; 82(13):2354-2356. PubMed ID: 35788291
[TBL] [Abstract][Full Text] [Related]
20. MRI texture analysis based on 3D tumor measurement reflects the IDH1 mutations in gliomas - A preliminary study.
Han L; Wang S; Miao Y; Shen H; Guo Y; Xie L; Shang Y; Dong J; Li X; Wang W; Song Q
Eur J Radiol; 2019 Mar; 112():169-179. PubMed ID: 30777207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]